Evidence map›Paper›PMID 40469103›Full record

ArticleiScience2025

Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells.

Nicolai Stransky, Ranran Ji, Lukas Prause, Katrin Ganser, Winfried S Wels, Peter Ruth, Stephan M Huber, Franziska Eckert

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicolai StranskyDepartment of Radiation Oncology, University Hospital Tübingen, 72076 Tübingen, Germany.
Ranran JiDepartment of Radiation Oncology, University Hospital Tübingen, 72076 Tübingen, Germany.
Lukas PrauseDepartment of Radiation Oncology, University Hospital Tübingen, 72076 Tübingen, Germany.
Katrin GanserDepartment of Radiation Oncology, University Hospital Tübingen, 72076 Tübingen, Germany.
Winfried S WelsGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
Peter RuthDepartment of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, 72076 Tübingen, Germany.
Stephan M HuberDepartment of Radiation Oncology, University Hospital Tübingen, 72076 Tübingen, Germany.
Franziska EckertDepartment of Radiation Oncology, University Hospital Tübingen, 72076 Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptors - natural killer (CAR-NK) cells are a promising new cancer treatment approach. They possess distinct benefits over CAR-T cells, including an intrinsic ability to differentiate between malignant and non-malignant cells, and a lower risk of graft-versus-host disease. Here, we evaluated two CAR-NK-92 cell lines, targeting either CD276 or HER2, and their potential on-target/off-tumor effects

Indexed as

Biological sciencesComponents of the immune systemImmunologySpecialized functions of cells

Identifiers

PMID40469103
PMCPMC12135394

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.